New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 4, 2014
08:03 EDTHALOHalozyme announces temporary halt of Phase 2 trial enrollment for PEGPH20
Halozyme announced that as a result of a recommendation received yesterday from an independent Data Monitoring Committee, it is temporarily halting patient enrollment and dosing of PEGPH20 in an ongoing Phase 2 trial evaluating PEGPH20 in patients with pancreatic cancer. The DMC is assessing clinical data that indicates a possible difference in the thromboembolic event rate between the group of patients treated with PEGPH20, nab-paclitaxel and gemcitabine versus the group of patients treated with nab-paclitaxel and gemcitabine without PEGPH20. The company is halting enrollment and dosing of PEGPH20 as precautionary actions while the DMC's full evaluation of the data is ongoing.
News For HALO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 11, 2015
16:42 EDTHALOHalozyme sees FY15 revenue $85M-$95M, consensus $93.34M
Subscribe for More Information
16:41 EDTHALOHalozyme reports Q1 EPS (12c), consensus (13c)
Subscribe for More Information
15:00 EDTHALONotable companies reporting after market close
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use